PsychoGenics Appoints Mark Day, Ph.D. as Senior Director, Cognitive
Neuroscience
This New Appointment Reflects the Company’s
Commitment to Cognition
TARRYTOWN, N.Y. (Business Wire EON) April 3, 2008 --
PsychoGenics Inc., announced the appointment of Mark Day, Ph.D., as
Senior Director, Cognitive Neuroscience. This appointment reflects the
company’s expansion and commitment to the
cognitive neurosciences.
Prior to this appointment, Dr. Day led and supported several programs
aimed at developing cognitive treatments for Schizophrenia and for
Alzheimer’s at Wyeth Neuroscience and at
GlaxoSmithKline. While at Wyeth, he also led the Discovery Translational
Neuroscience efforts and was responsible for the development and
implementation of discovery and clinical biomarkers to attenuate
clinical attrition rates in Phase II. Dr. Day has extensive experience
in developing novel behavioral models of learning and has employed these
models to dissociate the circuitry involved in encoding, consolidation
and recall of memory.
“PsychoGenics is committed to further
expanding its efforts in cognitive neuroscience,”
explained Dr. Emer Leahy, President and CEO. “We
are delighted that Mark has agreed to join the company to direct our
cognitive neuroscience group which includes several talented senior
scientists and associates. Mark will play an active role in developing
novel models of learning, including high throughput models which will be
employed in psychiatric and neurodegenerative drug discovery. I am
confident Mark will add significant value to PsychoGenics’
internal and partnered research and his drug development expertise will
be a great asset as we continue to expand our drug discovery programs.”
PsychoGenics’ Cognitive Neuroscience group has
developed numerous standard behavioral tests such as novel object
recognition and Morris water maze and is actively developing additional
tests such as the 5-choice serial reaction test, and experimental models
of temporally graded amnesia. Building on its successful in vivo
psychiatric drug discovery platform, the group is also developing novel
high throughput cognitive platforms that capture long term memory
processes and short term memory and executive functions to help identify
drug candidates for the treatment of cognitive impairment associated
with psychiatric and neurodegenerative disorders, such as schizophrenia,
attention deficit/hyperactivity disorder (ADHD), and Alzheimer’s
disease. PsychoGenics further supports internal and partnered drug
discovery with several neuropsychiatric mouse models, including
genetically modified models of Huntington’s
disease, Alzheimer’s disease, and ADHD.
About PsychoGenics:
PsychoGenics is a leader in preclinical behavioral neurobiology and a
provider of customized and innovative solutions for central nervous
system (CNS) drug discovery. PsychoGenics works with pharmaceutical and
biotechnology companies, academic institutions and not-for-profit
research foundations to address such major neurological disorders as:
ALS, Huntington’s Disease, anxiety, cognitive
impairment, depression, psychosis/schizophrenia and SMA. PsychoGenics
supports the understanding and treatment of CNS disorders by offering an
extensive range of established and customized validated in vivo
behavioral tests, behavioral pharmacology, phenotyping, bioinformatics,
microdialysis and radiotelemetry.
Post Comment:
Trackback URL: http://eon.businesswire.com/pingpr.php/RW1wdC1Db3VwLUhhbGYtWmV0YS1TdW1tLVplcm8=
Bookmark -
Del.icio.us |
Digg |
Furl It |
Spurl |
RawSugar |
Simpy |
Shadows |
Blink It |
My Web
|
